Quantitative Histopathology Analysis

Supporting hospitals and laboratories with digital advancements that can extend slide longevity, classify thousands of cells in real-time and facilitate the evaluation process towards more accurate results.

In recent years, molecular pathology has emerged as an imperative tool in treating cancer. Molecular pathology is used primarily to diagnose disease and guide the prevention and treatment of disease and is typically coupled with anatomic pathology. The most important molecular pathology test is Immunohistochemistry (IHC). Treatment of breast cancer, for example, relies primarily on analysis of a panel of IHC slides of different molecular targets.

Contrary to classic histopathology, which is based on qualitative assessment of the morphology of cells within a tumor, molecular pathology techniques are intrinsically quantitative and give statistically-based results. IHC uses special antibodies to label target compounds, typically proteins, which are then visualized in specific parts within cells and are counted one-by-one.

Manual counting is dependent on human subjectivity

Despite the inherent quantitative nature of IHC tests, these still rely on manual counting by the pathologist and are thus, once again, dependent on human subjectivity. Computer-aided (CA) systems are ideal in such cases, because a computer...
is fundamentally “good at counting”. Such systems analyze and count IHC-labeled cells within captured frames of defined tumor regions, with high precision and accuracy.

A good example of the benefits of using a computer-aided system for quantitative analysis is the Ki67 IHC test. This is a cell proliferation marker that is used to stratify good and poor prognostic categories in invasive breast cancer. The CAP guideline for Ki67 is to score at least 1000 tumor cells and calculate the percentage of positive cells within the tumor region¹. This is inherently difficult and time consuming for the pathologist and leads to lack of standardization or consistency in results.

Computer-aided systems, on the other hand, can very efficiently perform this type of analysis. In Figure 1, image analysis was performed on a Ki67 slide using ASI’s HiPath™ system. For this specific frame, 480 nuclei were captured and analyzed within seconds with a final score of 18.7% positivity for the slide, placing this case in the category of high proliferation for Ki67. In other words, based on a 15% threshold, this sample is positive for Ki67. The yellow rectangle is a zoom-in into a defined region within this frame. Note the accuracy of the system in counting each individual cell.
HER2/neu represents an additional challenging IHC test. Scoring in this case depends on precise identification and classification of cell-membrane. In Figure 2 below, a HER2/neu test was performed using HiPath™. Here again, computer-aided or digital analysis was used to accurately separate between membranes and nuclei and then classify and count each individual cell within the selected tumor region. Note the clear visualization of membrane in each individual cell. This is imperative for scoring of HER2/neu samples and is related directly to treatment with Herceptin (Roche).
The benefits of using computer-aided analysis in molecular pathology are beyond question. New IHC targets, such as PD-L1, are becoming an imperative part in treating cancer. Many of these new assays are difficult to analyze and thus require the aid of a computer. Automation and computer-aided systems will inevitably become an integral part of the daily work for pathologists and laboratories.

The advantage of the ASI software is in its ability to provide statistical data from the images captured. This not only creates a baseline for the analysis but also standardizes the workflow process so that the reporting results may not deviate from test to test. By neutralizing arbitrary decision making from every step of the visualization and analysis process, and instead implementing objective or digital instrumentation for cell classification, the may be less biased.

The pathologist is still at the center of the evaluation.
Nevertheless, the pathologist is still at the center of the evaluation. The pathologist can supersede every step of the evaluation and analysis process. The ASI software system helps with the visualization and interpretation, not in overcoming or overwriting expert evaluation. On the contrary, the software and algorithms are part of an open and flexible platform, which enables scientific experts to conduct analysis by reviewing the whole slide, focusing on regions of interest and adding new cell classifications for analysis.

The benefits of automation and digital advancements in scanning to visualization to analysis to reporting are wide and far. Digital tools and instrumentations can provide: 1) a systematized workflow approach, 2) faster turnaround time 3) more accurate results on thousands of cells, 4) economy of scale or cost-effective advantages 5) remote sharing capabilities so pathologist may sign off from a different location, 6) secure archiving for retrieval or data for deep learning, 7) extended slide longevity, etc.

¹ J Natl Cancer Inst. 2011; 103: 1656–1664

About Applied Spectral Imaging:

Applied Spectral Imaging (ASI) is a global leader in biomedical imaging with a comprehensive product portfolio and a global distribution footprint. The Company’s technology, powered by GenASIs, enables Pathology, Cytogenetics and Research laboratories to provide advanced diagnostics to patients. ASI has a wide portfolio of dedicated solutions for Brightfield, Fluorescence and Spectral imaging and analysis, including HiPath Pro, PathFusion, HiBand, HiFISH, Harmony and Rainbow.

Founded in 1993, ASI markets, services and supports its products in nearly 50 countries. The Company has worldwide offices in the US and Asia and a global network of distribution partners.